logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Navidea Biopharmaceuticals: Why This Small Firm's Stock Skyrocketed

Navidea Biopharmaceuticals Stock Soared Navidea Biopharmaceuticals ( NAVB ) stock price jumped from $1.27 to $3.04 this morning. The reason for the stock's soaring, according to the firm’s press release, was that interim data from a trial have further corroborated...

Read More

May 22, 2020

0

Why the new approval of Exelixis' blood pressure drug Minnebro in Japan is important

Exelixis collaborator, Daiichi Sankyo, Receives Regulatory Approval for MINNEBRO™ (Esaxerenone) Tablets for Hypertension in Japan Exelixis (EXEL)   and  Daiichi Sankyo  announced that the the Japanese Ministry of Health, Labor and Welfare  (MHLW) has approved Minnebro™ ( esaxerenone) tablets of ,1.25...

Read More

January 9, 2019

0

The Beginning of a Nektar Outperformance?

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics ( NKTR ) and Bristol-Myers Squibb ( BMY ) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar's bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into...

Read More

January 11, 2020

0

Another drug approval for Exelixis. Why Alnylam's stock is under pressure today

More good news came  from Exelixis (EXEL) . It  was expected by many but not by those who ignore the good news in favor of any negative news or lack of news. The announced news is that the FDA approved Exelixis’...

Read More

January 15, 2019

0

CompuGen demonstrates the importance of its product COM701 targeting PVRIG in immunotherapy

Data published in Cancer Immunology Research indicate monotherapy and combination opportunities for COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG CompuGen (CGEN)   announced the online publication of preclinical data demonstrating the role of PVRIG as a novel immune checkpoint...

Read More

January 22, 2019

0

Why Moderna Stock Is Boosted in Today's Bad Stock Market Day

Coronavirus On January 7, 2020, a novel coronavirus ( 2019-nCoV ) was identified in humans in Wuhan City, Hubei Province, China. Additional cases have been found in the United States and in a growing number of countries around the world....

Read More

January 27, 2020

0

A Potential Merger Between AstraZeneca Plc and Gilead Sciences?

AstraZeneca Plc and Gilead Sciences Potential Merger News spread through the media announcing that AstraZeneca Plc ( AZN ) has approached Gilead Sciences ( GILD ) regarding a possible, potential merger. People familiar with the subject (we don’t know who...

Read More

June 8, 2020

0

OncoCyte liquid biopsy proves its accuracy and superiority in the differential diagnoses of Lung Cancer

Can a liquid biopsy test be accurate enough for physicians to rely on in differentiating between malignant and benign lung nodules in early stage lung cancer and probably other cancers?   A Yes answer has come out from OncoCyte Corporation...

Read More

January 29, 2019

0

Celldex Therapeutics: The Beginning of the Firm's Resurrection

Celldex Therapeutics A few years ago Celldex Therapeutics ( CLDX ) was known for its superior pipeline products. The most promising product in the firm's pipeline was Celldex’s lead drug designed to treat the untreatable terrible brain cancer known as...

Read More

June 12, 2020

0

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease Designation for Batten Disease Condition known as CLN2

FDA Granted Rare Pediatric Disease Designation for RegenxBio's Product RGX-181 for CLN2 RegenxBio RegenxBio (RGNX) , a development-stage firm that focuses on designing and developing gene therapy based on its proprietary NAV ®  Technology Platform, announced that the U.S. FDA granted...

Read More

February 1, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 78
  • 79
  • 80
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy